职业生涯中期研究员奖-猫眼课题宝

职业生涯中期研究员奖

批准号：

8531887

负责人：

Stephen Jay Freedland

金额：

$17.55万

依托单位：

DUKE UNIVERSITY

依托单位国家：

美国

项目类别：

财政年份：

2012

资助国家：

美国

项目状态：

已结题

起止时间：

2012-08-16 至 2017-07-31

来源：

https://reporter.nih.gov/project-details/8531887

关键词：

Adverse effects Affect Aftercare Androgens Award Biological Markers Body Weight Body Weight decreased C-reactive protein Cancer Biology Cancer Patient Carbohydrates Clinical Clinical Trials Cohort Studies Diet Disease Disease Progression Exercise Faculty Fatty acid glycerol esters Funding Future Generations Goals Growth Human In Vitro Insulin Intake Intervention Intervention Studies Leptin Life Style Link Malignant Neoplasms Malignant neoplasm of prostate Measures Mediator of activation protein Medical Oncology Medical Students Mentors Mentorship Mid-Career Clinical Scientist Award (K24)Morbidity - disease rate Mus Natural History Obesity Outcome Patients Phase Pilot Projects Pomegranate Population Process Prostate Cancer therapy Prostatic Public Health Radical Prostatectomy Recurrence Research Research Personnel Research Training Risk Role Scientist Serum Source Surgeon Testing Time Toxic effect Training Urologist Urology Weight adiponectin arm cancer therapy career clinical care deprivation diet and exercise dietary restriction dietary supplements glycemic control improved insulin signaling lifestyle intervention meetings men next generation oxidative damage patient oriented research prevent primary outcome programs prospective randomized trial secondary outcome trial comparing tumor progression urologic

项目摘要

项目成果

Stephen Jay Freedland的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): This Midcareer Investigator Award application seeks support to provide Dr. Freedland with protected time for patient-oriented research (POR) and to act as research mentor for junior faculty and 1 research fellow per year. Dr. Freedland's POR focuses on retrospective cohort studies with a transitioning emphasis on prospective clinical trials aimed at developing new and less toxic treatments to minimize prostate cancer treatment side effects and slow prostate cancer progression. Herein, he proposes a new trial comparing a carbohydrate-restricted diet vs. control for men with PSA recurrence after prostate cancer therapy aiming to slow the rate of PSA rise (lengthen the PSA doubling time), as an indirect measure of slowed prostate cancer growth. Secondary outcomes include weight loss and important prostate cancer biomarkers. Successful completion of this award will advance our understanding of lifestyle and other low toxicity interventions for prostate cancer as well as help educate the next generation of POR investigators.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文